EGFR and triple-negative breast carcinoma: Since triple-negative breast cancer is known to overexpress EGFR and the EGF receptor is a well-established cancer therapy target (Seshacharyulu et al., 2012), using E. coli OMVs and the ClyA displaying system, we introduced a platform with a capability of specifically targeting triple-negative breast cancer, which can be further employed for cancers overexpressing EGF receptors.